SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness

BACKGROUND: Additional epidermal growth factor receptor (EGFR) mutations confer the drug resistance to generations of EGFR targeted tyrosine kinase inhibitor (EGFR-TKI), posing a major challenge to developing effective treatment of lung adenocarcinoma (LUAD). The strategy of combining EGFR-TKI with...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Leiming, Yang, Fan, Wu, Xiao, Li, Suzhi, Kan, Chen, Zheng, Hong, Wang, Siying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254369/
https://www.ncbi.nlm.nih.gov/pubmed/34217295
http://dx.doi.org/10.1186/s12935-021-02056-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254369/
https://www.ncbi.nlm.nih.gov/pubmed/34217295
http://dx.doi.org/10.1186/s12935-021-02056-x

Ejemplares similares